We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The beginning of amyloid imaging
- Rapid growth research area
- Overview
- The story begins with Thioflavin-T
- Uncharged Thioflavin-T derivatives
- Can we REALLY see amyloid in vivo?
- First human PiB study
- in vivo PiB retention and Amyloid beta levels (1)
- in vivo PiB retention and Amyloid beta levels (2)
- in vivo PiB retention and Amyloid beta levels (3)
- in vivo PiB retention and Amyloid beta levels (4)
- Amyloid imaging in dementia
- In vivo pathology
- Amyloid imaging allows for 3-D quantization
- PET data are quantitative
- Voxel-wise comparisons
- Amyloid beta deposition and hypometabolism
- Regional & Voxel-wise comparisons
- Amyloid imaging in AD
- Striatal increase in PiB uptake in variant AD
- Amyloid beta variant favoring oligomerization in AD
- CSF Amyloid beta levels predict PIB retention
- CSF Amyloid beta and PiB retention correlation (1)
- CSF Amyloid beta and PiB retention correlation (2)
- CSF Amyloid beta levels and Brain Amyloid beta
- Confirming post-mortem studies(1)
- Confirming post-mortem studies (2)
- Do high PiB levels equal AD or mixed pathology?
- Lower amyloid prevalence in PD/PDD
- Amyloid distribution in cerebral amyloid angiopathy
- Do low PiB levels NOT equal AD?
- Amyloid imaging in MCI
- MCI subjects can have high or low PiB levels
- Most MCI patients have either high or low PiB
- PiB levels as predictors of clinical conversion (1)
- PiB levels as predictors of clinical conversion (2)
- Amyloid imaging in cognitively normal elderly
- Amyloid deposition in normal elderly (1)
- Amyloid deposition in normal elderly (2)
- Amyloid deposition in normal elderly (3)
- Fibrillar Amyloid beta burden in normal elderly
- PiB levels in AD vs. MCI (1)
- PiB levels in AD vs. MCI (2)
- The consequences of being amyloid-positive
- Reduction in metabolism in PiB positive subjects
- Greater brain atrophy in PiB positive normal elderly
- Cortical thinning in PiB positive normal elderly
- Memory impairment and PiB retention
- Clinical severity of AD and PiB uptake
- Amyloid beta cognition impairment
- Mitigation of Amyloid beta effects
- Does PiB retention increase over time?
- Group and individual changes in PiB retention
- PiB positive subjects increase slowly (1)
- PiB positive subjects increase slowly (2)
- Reliable change index
- Increase in PiB retention is relatively linear
- Two cognitively stable controls
- Emerging model - Amyloid beta requires mediators
- Conceptual model
- The Amyloid beta centric view
- Lower vulnerability to Amyloid beta
- Higher vulnerability to Amyloid beta
- Summary
- Collaborators and supporters
Topics Covered
- Amyloid imaging PET tracers
- Development and validation
- Amyloid imaging in dementia
- Amyloid imaging in mild cognitive impairment
- Amyloid imaging in cognitively normal elderly
- Consequences of being amyloid-positive
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klunk, W. (2020, May 1). Imaging amyloid: now that we can see it, what does it all mean? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/UAGD5937.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. William Klunk has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neurology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is William Klunk and
I'm Professor of Psychiatry and
Neurology at the University of
Pittsburgh School of Medicine.
I'm going to talk about imaging amyloid.
Now that we can see it,
what does it all mean?
0:14
We should remember that this is still
a very new field, in fact the first
presentation on the topic was given in
July of 2002 by Henry Engler at the 8th
International Conference on Alzheimer's
disease in Stockholm, Sweden.
It was the Swedish group that coined
the term 'PiB' or Pittsburgh compound-B.
0:35
Although new,
it's an area of rapid research growth,
in what we euphemistically refer to as our
'pibliography' or collection of papers
that refer to the use of pib in amyloid
imaging, you can see an exponential growth
over the past eight years, so that there
are now well over 150 papers and growing.
Of course I won't get to them all, but
I'll try to sample the highlights
to give an overview of the field.
1:02
By way of overview, what I'll be talking
about is: can we really see amyloid?
By that I mean: is there a good
pathological correlation between
what we see in vivo with a PET scan, and
what is actually in the brain that
we can later examine after death.
Then I want to talk
about what it all means,
I'll break these into
two general categories.
The first being to confirm what post
mortem studies have already told us.
There's a wealth of valuable information
from post mortem studies, but
of course this in vivo imaging was
developed to go beyond these limitations.
What we're going to talk about then
are things like longitudinal studies,
and all kinds of things that couldn't
be done with post mortem studies but
can potentially be done with this
new in vivo imaging technology.